Can you explain to me why you would have MSB ramp up production when there is no guarantee a product will be approved by FDA?
Why should MSB take the risk? If more die, it is on FDA's head for not approving use in aGVHD (despite 9 to 1 experts wanting it approved).
- Forums
- ASX - By Stock
- MSB
- Ann: Remestemcel-L FDA Fast Track Designation for COVID-19 ARDS
Ann: Remestemcel-L FDA Fast Track Designation for COVID-19 ARDS, page-430
-
- There are more pages in this discussion • 143 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MSB (ASX) to my watchlist
|
|||||
Last
$1.10 |
Change
-0.030(2.67%) |
Mkt cap ! $1.261B |
Open | High | Low | Value | Volume |
$1.14 | $1.16 | $1.09 | $3.504M | 3.142M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
23 | 125979 | $1.09 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.10 | 24813 | 8 |
Last trade - 11.29am 29/07/2024 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |